BiotechTube
Reprise Biomedical

Reprise Biomedical

San Diego, United States· Est.
reprisebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Reprise Biomedical is a private, commercial-stage biotech company founded in 2021 and headquartered in San Diego, with operational offices in Plymouth, MN. The company's core innovation is a proprietary perfusion decellularization process applied to liver tissue, producing collagen-rich, three-dimensional biologic scaffolds (Miro3D, MiroDerm, etc.) for the advanced wound care market. With a product portfolio already on the market and a focus on surgeon needs, Reprise operates in the lucrative biologics segment of the medical device industry, aiming to improve outcomes in complex wound healing.

Wound CareSoft Tissue Reinforcement

Technology Platform

Proprietary perfusion decellularization of liver tissue to create 3D collagen scaffolds with preserved vasculature architecture for rapid cellular integration.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The large and growing global advanced wound care market, particularly the biologic segment, offers significant expansion potential.
The company's 3D, vasculature-preserving scaffolds address a clear need in complex surgical wounds where current options are limited, providing a compelling value proposition to surgeons.

Risk Factors

Intense competition from large, established medtech firms and other biologic matrix providers poses a market penetration challenge.
The company also faces commercial execution risks, including securing adequate reimbursement and scaling its sales distribution effectively as a new, private entity.

Competitive Landscape

Reprise competes in the crowded advanced wound care biologics market against major players like Integra LifeSciences (PriMatrix, Cytal), Organogenesis (PuraPly, Affinity), and Smith & Nephew, as well as numerous other ECM-focused companies. Its differentiation is based on its proprietary perfusion decellularization process, which aims to offer a more structurally intact and integrative scaffold compared to traditional immersion-decellularized products.

More companies in Biologics / Biosimilars →More companies in United States →